Medigene AG (WBO:MDG1) Institutional Ownership : 1.42% (As of Apr. 29, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Medigene AG Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Medigene AG's institutional ownership is 1.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Medigene AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Medigene AG's Float Percentage Of Total Shares Outstanding is 0.00%.

Medigene AG Institutional Ownership Historical Data

The historical data trend for Medigene AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Institutional Ownership Chart

Medigene AG Historical Data

The historical data trend for Medigene AG can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	1.47	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.42

Medigene AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Medigene AG (WBO:MDG1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (WBO:MDG1) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

MDGEF:USA MDG1:Germany

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG (WBO:MDG1) Headlines

No Headlines